BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16019770)

  • 1. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine.
    Hedelin H; Johansson N; Ströberg P
    Scand J Urol Nephrol; 2005; 39(2):154-9. PubMed ID: 16019770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
    Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
    Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms.
    Laniado ME; Ockrim JL; Marronaro A; Tubaro A; Carter SS
    BJU Int; 2004 Dec; 94(9):1283-6. PubMed ID: 15610106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
    Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
    Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms.
    Vesely S; Knutson T; Damber JE; Dicuio M; Dahlstrand C
    Scand J Urol Nephrol; 2003; 37(4):322-8. PubMed ID: 12944191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older.
    Berges R; Oelke M
    World J Urol; 2011 Apr; 29(2):171-8. PubMed ID: 21221974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
    Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
    Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen and transition zone index - powerful predictors for acute urinary retention in men with benign prostatic hyperplasia.
    Milonas D; Trumbeckas D
    Medicina (Kaunas); 2003; 39(11):1071-7. PubMed ID: 14646460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
    Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J
    J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
    Mochtar CA; Kiemeney LA; van Riemsdijk MM; Barnett GS; Laguna MP; Debruyne FM; de la Rosette JJ
    Eur Urol; 2003 Dec; 44(6):695-700. PubMed ID: 14644122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia.
    Hochberg DA; Armenakas NA; Fracchia JA
    Prostate; 2000 Dec; 45(4):315-9. PubMed ID: 11102956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms.
    Shim HB; Lee JK; Jung TY; Ku JH
    Prostate Cancer Prostatic Dis; 2007; 10(2):143-8. PubMed ID: 17199133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.